RxDoctor Payments Data

Harry Li, MD

Internal Medicine · Columbia, MDNPI 1487711552

Payments from drug & device makers

$552in general payments, 2019–2025

Across 22 payments — averaging $25.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$223
  • Amgen$104
  • Biogen$64
  • Abbott$50
  • AbbVie$34
  • Pfizer$31
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$552100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead6$223
Amgen5$104
Biogen3$64
Abbott1$50
AbbVie2$34
Pfizer2$31
Novo Nordisk1$22
Amarin Pharma, Inc.1$13
Johnson & Johnson1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$552 in reported general payments places this provider in the 65th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$185,635
Medicare patients
407
Services billed
1,757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin139$106,974
Trelegy ElliptaFluticasone/Umeclidin/Vilanter102$64,930
EliquisApixaban52$52,023
MyrbetriqMirabegron101$48,007
VascepaIcosapent Ethyl174$46,034
JanuviaSitagliptin Phosphate62$41,361
XareltoRivaroxaban51$35,996
InvokanaCanagliflozin46$25,146
Tresiba Flextouch U-100Insulin Degludec33$21,204
TradjentaLinagliptin44$20,782
BrilintaTicagrelor35$14,958
LinzessLinaclotide24$12,390
FarxigaDapagliflozin Propanediol13$10,417
Diclofenac Sodium129$9,352
GemtesaVibegron16$9,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invokana$11$61,14297 claims
PfizerEliquis$31$52,02352 claims
AbbVieLinzess$34$12,39024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →